DK3398946T3 - Salt af morpholin-derivat og krystallin form deraf, samt fremstillingsfremgangsmåde, farmaceutisk sammensætning og anvendelse af samme - Google Patents
Salt af morpholin-derivat og krystallin form deraf, samt fremstillingsfremgangsmåde, farmaceutisk sammensætning og anvendelse af samme Download PDFInfo
- Publication number
- DK3398946T3 DK3398946T3 DK16881245.1T DK16881245T DK3398946T3 DK 3398946 T3 DK3398946 T3 DK 3398946T3 DK 16881245 T DK16881245 T DK 16881245T DK 3398946 T3 DK3398946 T3 DK 3398946T3
- Authority
- DK
- Denmark
- Prior art keywords
- salt
- well
- pharmaceutical composition
- same
- crystalline form
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/33—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
- C07C309/34—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
- C07C309/35—Naphthalene sulfonic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/42—Separation; Purification; Stabilisation; Use of additives
- C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/08—Acetic acid
- C07C53/10—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201511016783 | 2015-12-29 | ||
| PCT/CN2016/112966 WO2017114456A1 (zh) | 2015-12-29 | 2016-12-29 | 吗啉衍生物的盐及其晶型、其制备方法及药物组合物、用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3398946T3 true DK3398946T3 (da) | 2022-08-08 |
Family
ID=59224612
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16881245.1T DK3398946T3 (da) | 2015-12-29 | 2016-12-29 | Salt af morpholin-derivat og krystallin form deraf, samt fremstillingsfremgangsmåde, farmaceutisk sammensætning og anvendelse af samme |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10519150B2 (da) |
| EP (1) | EP3398946B1 (da) |
| JP (1) | JP6818031B2 (da) |
| CN (3) | CN113816952A (da) |
| DK (1) | DK3398946T3 (da) |
| ES (1) | ES2918674T3 (da) |
| HU (1) | HUE059444T2 (da) |
| PL (1) | PL3398946T3 (da) |
| PT (1) | PT3398946T (da) |
| TW (1) | TWI705065B (da) |
| WO (1) | WO2017114456A1 (da) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114129569A (zh) * | 2020-09-04 | 2022-03-04 | 上海医药集团股份有限公司 | 一种含氮的饱和杂环化合物的应用 |
| WO2022047730A1 (en) * | 2020-09-04 | 2022-03-10 | Shanghai Pharmaceuticals Holding Co., Ltd. | Methods to treat inflammatory bowel disease |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003519698A (ja) * | 2000-01-07 | 2003-06-24 | トランスフォーム ファーマスーティカルズ，インコーポレイテッド | 多様な固体形態のハイスループットでの形成、同定および分析 |
| MX349484B (es) * | 2011-03-16 | 2017-07-31 | Mitsubishi Tanabe Pharma Corp | Compuesto heterocíclico saturado que contiene nitrógeno. |
| CN104640847B (zh) * | 2012-09-14 | 2019-10-15 | 上海医药集团股份有限公司 | 新型肾素抑制剂 |
| JP5764628B2 (ja) * | 2012-09-14 | 2015-08-19 | 田辺三菱製薬株式会社 | 医薬組成物 |
-
2016
- 2016-12-29 CN CN202110801274.0A patent/CN113816952A/zh active Pending
- 2016-12-29 CN CN201611246909.0A patent/CN106928218B/zh active Active
- 2016-12-29 ES ES16881245T patent/ES2918674T3/es active Active
- 2016-12-29 US US16/066,490 patent/US10519150B2/en active Active
- 2016-12-29 TW TW105143910A patent/TWI705065B/zh active
- 2016-12-29 PL PL16881245.1T patent/PL3398946T3/pl unknown
- 2016-12-29 DK DK16881245.1T patent/DK3398946T3/da active
- 2016-12-29 WO PCT/CN2016/112966 patent/WO2017114456A1/zh active Application Filing
- 2016-12-29 PT PT168812451T patent/PT3398946T/pt unknown
- 2016-12-29 HU HUE16881245A patent/HUE059444T2/hu unknown
- 2016-12-29 CN CN202110794158.0A patent/CN113816951B/zh active Active
- 2016-12-29 EP EP16881245.1A patent/EP3398946B1/en active Active
- 2016-12-29 JP JP2018534034A patent/JP6818031B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3398946A4 (en) | 2019-08-28 |
| EP3398946A1 (en) | 2018-11-07 |
| CN113816951B (zh) | 2022-09-27 |
| CN113816952A (zh) | 2021-12-21 |
| CN113816951A (zh) | 2021-12-21 |
| CN106928218B (zh) | 2021-08-03 |
| JP6818031B2 (ja) | 2021-01-20 |
| TW201722950A (zh) | 2017-07-01 |
| TWI705065B (zh) | 2020-09-21 |
| HUE059444T2 (hu) | 2022-11-28 |
| CN106928218A (zh) | 2017-07-07 |
| WO2017114456A1 (zh) | 2017-07-06 |
| US20190016718A1 (en) | 2019-01-17 |
| US10519150B2 (en) | 2019-12-31 |
| ES2918674T3 (es) | 2022-07-19 |
| PL3398946T3 (pl) | 2022-10-10 |
| JP2019500385A (ja) | 2019-01-10 |
| EP3398946B1 (en) | 2022-05-04 |
| PT3398946T (pt) | 2022-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL286428A (en) | Disubstituted heterocyclyl derivatives as inhibitors of cyclin-dependent kinases | |
| HK1243999A1 (zh) | 新型3-吲哚取代的衍生物、藥物組合物及使用方法 | |
| DK3319956T3 (da) | Substituerede oxopyridinderivater | |
| DK3497081T3 (da) | Fremgangsmåde til fremstilling af 4-ammonium-2,2,6,6-tetraalkylpiperidinylsalte | |
| DK3191406T3 (da) | Fremgangsmåde til fremstilling af aluminiumchloridderivater | |
| DK3255042T3 (da) | Heterocyklisk forbindelse og farmaceutisk sammensætning omfattende samme | |
| DK3429998T3 (da) | Fremgangsmåde til fremstilling af quinolin-2-yl-phenylaminderivater og disses salte | |
| HK1253575A1 (zh) | 作為mnk抑制劑的稠合噻唑並嘧啶衍生物 | |
| DK3278801T3 (da) | Farmaceutisk sammensætning indeholdende mirabegron | |
| DK3390407T3 (da) | Fremgangsmåder til fremstilling af heterocykliske 1,3-benzodioxolforbindelser | |
| DK3185867T3 (da) | Krystalliseringsfremgangsmåde af aripiprazolderivater i forlængede frigivelsesformuleringer til behandling af skizofreni | |
| DK3390412T3 (da) | Vandopløselige derivater af 3,5-diphenyl-diazolforbindelser | |
| DK3302573T3 (da) | Sammensætning til behandlingen af hjernelæsioner | |
| DK3248981T3 (da) | C14-hydroxyl-forestrede aminosyrederivater af triptolid, og fremstillingsfremgangsmåde og anvendelse deraf | |
| DK3157506T3 (da) | Smagsmaskeret oral, farmaceutisk sammensætning | |
| DK3452465T3 (da) | Substituerede 2,4-diaminoquinolinderivater til anvendelse til behandling af proliferative sygdomme | |
| DK3164123T3 (da) | Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier | |
| DK3398946T3 (da) | Salt af morpholin-derivat og krystallin form deraf, samt fremstillingsfremgangsmåde, farmaceutisk sammensætning og anvendelse af samme | |
| DK3313370T3 (da) | Oftalmologisk farmaceutisk sammensætning | |
| DK3484875T3 (da) | Pyrazolylaminobenzimidazolderivater som JAK-hæmmere | |
| DK3500572T3 (da) | Cytisinderivater til behandling af afhængighed | |
| KR20180084728A (ko) | 구강용 조성물 | |
| EP3215552A4 (en) | Derivatives of 1,3-propanediol | |
| DK3424500T3 (da) | Farmaceutisk sammensætning, der omfatter famitinib | |
| DK3381914T3 (da) | Fremgangsmåde til oprensning af benzopyranderivat, krystallinsk form deraf og fremgangsmåde til fremstilling af den krystallinske form |